SnoRNAs: the promising targets for anti-tumor therapy

doi: 10.1016/j.jpha.2024.101064

• Xiaoyun Hu^a,b,c , 
• Wanlin Cui^a,b , 
• Min Liu^a,b , 
• Fangxiao Zhang^d , 
• Yingqi Zhao^a,b , 
• Mingrong Zhang^a,b , 
• Yuhang Yin^a,b , 
• Yalun Li^e , 
• Ying Che^a,b , 
• Xianglong Zhu^a,b , 
• Yuxuan Fan^a,b , 
• Xiaolan Deng^{f ,  ,}  , 
• Minjie Wei^{a,b,c,g ,  ,}  , 
• Huizhe Wu^{a,b,c,g ,  ,} 

• a Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, P. R. China;

• b Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation, Liaoning Cancer immune peptide drug Engineering Technology Research Center, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, P. R. China;

• c Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, 110122, P. R. China;

• d The Second Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, 110001, P. R. China;

• e Department of Anorectal Surgery, The First Affiliated Hospital of China Medical University, Shenyang, 110001, P. R. China;

• f Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA;

• g Shenyang Kangwei Medical Laboratory Analysis Co. LTD, Shenyang, 110000, P. R. China